Marinus Pharmaceuticals in Radnor, PA is a clinical stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.
Marinus is committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders. We are developing an investigational drug, ganaxolone, which is an innovative and much needed potential treatment option for children and adults.
At Marinus, we use a strong scientific rationale, determination, and expertise to embrace the challenge of developing treatments in rare epilepsy and neuropsychiatric disorders. We are committed to our patients, physicians, and epilepsy community, as we plan our path forward to providing much needed options for patients.